Press release 📈 Stocks 🌍 China

Innovent Biologics Adds 7 Drugs to China's 2026 National Reimbursement List

Innovent Biologics secures NRDL inclusion for seven innovative products effective January 1, 2027, expanding its reimbursed lineup to 17 drugs and enhancing market access for key therapies like mazdutide.

📅 November 14, 2026 🕐 1 min read

2 assets impacted (Stocks). Net bias: 2 Bullish, 0 Bearish, 0 Neutral. Strongest signal: 01801.HK ↑ 5/10 (70% confidence).

📊 Affected Assets (2)

01801.HK

Bullish 🤖 70%

📆 Mid-term 🌍 CN · Explicit

Seven Innovent products, including first-in-class mazdutide and PECONDLE®, were added to China's 2026 National Reimbursement Drug List effective January 1, 2027, expanding the reimbursed lineup to 17 drugs. NRDL access typically drives significant volume growth for the covered drugs, a concrete commercial catalyst. The annual NRDL round is, however, a recurring and partly anticipated event, which limits the surprise factor.

Catalysts

▲ NRDL inclusion of four new products (mazdutide, PECONDLE®, TABOSUN®, Vanflyta®) effective January 1, 2027
▲ Two new indications for TYVYT® (sintilimab) added to reimbursement

Risk Factors

▼ NRDL inclusion usually comes with negotiated price cuts, so reimbursement volume gains may be partly offset by lower per-unit pricing
▼ The article gives no revenue or sales figures, so the financial magnitude is not quantified

LLY

Bullish 🤖 50%

📆 Mid-term 🌍 US ✨ Inferred

Eli Lilly licensed mazdutide (OXM3) to Innovent for China and also partners on sintilimab and licenses Jaypirca for Chinese commercialization. NRDL inclusion of these products from January 1, 2027 broadens their Chinese market, a modest positive for Lilly, though Innovent handles commercialization and no financial terms are disclosed.

Catalysts

▲ Mazdutide, out-licensed by Lilly for China, newly included in the 2026 NRDL effective January 1, 2027

Risk Factors

▼ Innovent is the commercializer in Mainland China, so the direct revenue benefit to Lilly is not stated

🧭 Full analysis of these assets

🎯 Key Takeaways

Seven innovative products were added to the 2026 NRDL, with coverage taking effect on January 1, 2027.
The company's total reimbursed drug lineup has expanded to 17 products, cumulatively benefiting over 20 million patients.
Mazdutide, a GCG/GLP-1 dual receptor agonist, is now included for the treatment of type 2 diabetes in adults.
Two new indications for TYVYT® (sintilimab) were added to the reimbursement list, covering colon cancer and renal cell carcinoma.
PECONDLE® (picankibart) was included for adult patients with moderate to severe plaque psoriasis.

📝 Executive Summary

Innovent Biologics announced that seven of its innovative products, including mazdutide and PECONDLE®, have been successfully included in China's 2026 National Reimbursement Drug List (NRDL). The updated list, which takes effect on January 1, 2027, expands the company's reimbursed portfolio to 17 products, aiming to improve patient access to treatments for oncology, autoimmune, and metabolic diseases.

❓ FAQ

01801.HK · What happened to Innovent's drugs?

Seven of Innovent's innovative products were successfully added to China's 2026 National Reimbursement Drug List, which takes effect on January 1, 2027, meaning Chinese patients will get these medicines reimbursed.

01801.HK · Why does this matter for the stock?

Reimbursement listing generally makes the covered drugs accessible to far more patients — Innovent's reimbursed lineup grows to 17 products — which supports future sales of drugs like mazdutide and picankibart.

LLY · Does the NRDL inclusion benefit Eli Lilly?

Indirectly: mazdutide was developed under an exclusive license agreement with Lilly, and its inclusion in the 2026 NRDL expands its reimbursed market in China, though Lilly is not the commercializer there.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article